Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines Sandoz, a global leader in generic and biosimilar…
Browsing: Novartis
Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant…
Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Pivotal Phase III APPLY-PNH trial Novartis has…